Bruker Corporation (BRKR)
NASDAQ: BRKR · Real-Time Price · USD
39.66
+0.93 (2.40%)
At close: Jun 24, 2025, 4:00 PM
39.59
-0.07 (-0.18%)
After-hours: Jun 24, 2025, 5:44 PM EDT
Bruker Revenue
Bruker had revenue of $801.40M in the quarter ending March 31, 2025, with 11.04% growth. This brings the company's revenue in the last twelve months to $3.45B, up 14.84% year-over-year. In the year 2024, Bruker had annual revenue of $3.37B with 13.56% growth.
Revenue (ttm)
$3.45B
Revenue Growth
+14.84%
P/S Ratio
1.69
Revenue / Employee
$302,396
Employees
11,396
Market Cap
6.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.37B | 401.90M | 13.56% |
| Dec 31, 2023 | 2.96B | 433.80M | 17.14% |
| Dec 31, 2022 | 2.53B | 112.80M | 4.67% |
| Dec 31, 2021 | 2.42B | 430.40M | 21.66% |
| Dec 31, 2020 | 1.99B | -85.10M | -4.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BRKR News
- 11 hours ago - Bruker Experiences Growth in Semiconductor Advanced Packaging Market Fueled by AI Demands - Business Wire
- 21 days ago - Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection - Business Wire
- 21 days ago - Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics - Business Wire
- 22 days ago - Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics - Business Wire
- 22 days ago - Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity - Business Wire
- 25 days ago - Bruker Corporation to Present at the Jefferies Global Healthcare Conference - Business Wire
- 25 days ago - Bruker Launches Revolutionary timsOmniTM Mass Spectrometer - Business Wire
- 25 days ago - Bruker Launches Novel timsMetabo™ Mass Spectrometer for Breakthrough 4D-Metabolomics and 4D-Lipidomics Sensitivity, Specificity and Annotation Confidence - at Speed, Depth, and Scale - Business Wire